Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
ICD-10 C47.11 is a billable code used to indicate a diagnosis of malignant neoplasm of peripheral nerves of right upper limb, including shoulder.
C47.11 refers to malignant neoplasms affecting the peripheral nerves in the right upper limb, including the shoulder region. These tumors can arise from various types of cells within the peripheral nervous system, including Schwann cells, which are responsible for the myelin sheath surrounding nerves. Soft tissue sarcomas, a category of malignant tumors, can also involve peripheral nerves, leading to complex clinical presentations. Symptoms may include pain, weakness, and sensory changes in the affected limb. Diagnosis typically involves imaging studies such as MRI or CT scans, followed by biopsy for histological confirmation. Treatment often requires a multidisciplinary approach, including surgical resection, radiation therapy, and chemotherapy, depending on the tumor's grade and stage. Grading of these tumors is crucial, as it influences prognosis and treatment strategies. High-grade tumors tend to be more aggressive and may require more intensive treatment regimens. The management of these neoplasms necessitates collaboration among oncologists, surgeons, radiologists, and pain management specialists to optimize patient outcomes.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Diagnosis and management of soft tissue sarcomas involving peripheral nerves.
Ensure accurate grading and staging of tumors to guide treatment.
Operative reports detailing the extent of resection and any nerve involvement.
Surgical intervention for tumor resection in the upper limb.
Documenting nerve repair or reconstruction if performed.
Used when lymph nodes are sampled for staging of the malignancy.
Pathology report and imaging studies must be included.
Oncologists must ensure accurate staging documentation.
Tumor grading is crucial as it determines the aggressiveness of the cancer and influences treatment decisions. High-grade tumors may require more aggressive treatment compared to low-grade tumors.
